Aravive, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2014-12-11: Form 8-K; Period of report 2014-12-09; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2014-11-06: Form 8-K; Period of report 2014-11-06; Description 2.02 Results of Operations and Financial Condition.
- 2014-09-22: Form 8-K; Period of report 2014-09-20; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2014-08-05: Form 8-K; Period of report 2014-08-05; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2014-12-11 | 8-K | 2014-12-09 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 9, 2014, Francesco De Rubertis notified Versartis, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company (the “Board”), effective December 9, 2014. | vsar-8k_20141211.htm |
| 2014-11-06 | 8-K | 2014-11-06 | 2.02 Results of Operations and Financial Condition | vsar-8k_20140805.htm | |
| 2014-09-22 | 8-K | 2014-09-20 | 7.01 Regulation FD Disclosure | 7.01 Spokespersons of Versartis, Inc. (the “Company”) presented the information in the presentation poster attached hereto as Exhibit 99.1 at the European Society for Paediatric Endocrinology’s 53rd Annual Meeting (ESPE 2014) in Dublin, Ireland on September 20, 2014. | d791341d8k.htm |
| 2014-08-05 | 8-K | 2014-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2014, Versartis, Inc. (the “Company”) issued a press release announcing its financial results for the three- and six-month periods ended June 30, 2014. | d767704d8k.htm |
| 2014-07-25 | 8-K | 2014-07-21 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 21, 2014, Michael Dybbs notified Versartis, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company (the “Board”), effective immediately. | d762600d8k.htm |
| 2014-06-23 | 8-K | 2014-06-23 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 Spokespersons of Versartis, Inc. (the “Company”) plan to present the information in the presentation poster attached hereto as Exhibit 99.1 at the 16th International Congress of Endocrinology and The Endocrine Society’s 96th Annual Meeting and Expo (ICE/ENDO 2014) in Chicago, IL on June 23, 2014. 8.01 On June 23, 2014, the Company announced positive Phase 2a data from its six month clinical trial demonstrating the safety and efficacy of VRS-317 in the treatment of naïve, pre-pubertal children with growth hormone deficiency (GHD). | d743904d8k.htm |
| 2014-06-13 | 8-K | 2014-06-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 11, 2014, the Compensation Committee (the “Compensation Committee”) of the Board of Directors of Versartis, Inc. (the “Company”) approved (a) an increase in the base salary, (b) an increase in the target annual bonus as a percentage of salary, (c) grants of options (the “Options”) and (d) grants of restricted stock units (the “RSUs”) for each of the Company’s named executive officers (as defined in Item 402(a)(3) of Regulation S-K promulgated by the Securities and Exchange Commission), as set forth in the table below. | d742234d8k.htm |
| 2014-05-05 | 8-K | 2014-05-05 | 2.02 Results of Operations and Financial Condition | 2.02 On May 5, 2014, Versartis, Inc. (the “Company”) issued a press release announcing its financial results for the three month period ended March 31, 2014. | d723490d8k.htm |
| 2014-04-17 | 8-K | 2014-04-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 15, 2014, the Compensation Committee (the “Compensation Committee”) of the Board of Directors of Versartis, Inc. (the “Company”) approved (a) one-time cash bonus payments and (b) grants of restricted stock units (the “RSUs”) for each of the Company’s named executive officers (as defined in Item 402(a)(3) of Regulation S-K promulgated by the Securities and Exchange Commission), as set forth in the table below. | d712729d8k.htm |
| 2014-03-26 | 8-K | 2014-03-26 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On March 26, 2014, Versartis, Inc., a Delaware corporation (the “Company”), filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of shares of its common stock. | d700102d8k.htm |